GlassScriptPhysician profile
Randal Pham
NPI 1275626897
$11,519.03
in general payments reported to CMS, 2019-2025
34 companies · $1,229 in 2025
The $1,229 reported for 2025 was more than what 90% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,121 · 2020: $1,189 · 2021: $2,099 · 2022: $1,960 · 2023: $1,684 · 2024: $1,238 · 2025: $1,229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,150.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $1,455.52 | 2022-2025 | Tyrvaya |
| Mallinckrodt Hospital Products INC. | $1,162.97 | 2020-2024 | Acthar |
| Alcon Vision LLC | $1,031.69 | 2021-2025 | Rocklatan, Tryptyr, Rhopressa |
| Abbvie INC. | $906.11 | 2019-2025 | |
| Allergan, INC. | $874.24 | 2019-2022 | |
| Horizon Therapeutics Plc | $763.97 | 2019-2023 | Tepezza |
| Novartis Pharmaceuticals Corporation | $589.49 | 2019-2023 | |
| Bausch & Lomb Americas INC. | $521.46 | 2022-2025 | Vyzulta, Miebo, Prolensa |
| Aerie Pharmaceuticals, INC. | $465.29 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $420.09 | 2019-2021 | |
| Omeros Corporation | $302.30 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $289.34 | 2024-2025 | Purified Cortrophin Gel |
| Kala Pharmaceuticals, INC. | $274.23 | 2020-2022 | |
| Galderma Laboratories, L.P. | $263.58 | 2019-2020 | |
| Biotissue Holdings INC. | $262.33 | 2021-2023 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $259.38 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $253.61 | 2019-2021 | |
| Dompe US, INC. | $219.24 | 2020-2025 | Oxervate |
| Thea Pharma INC. | $211.79 | 2024 | Iyuzeh |
| Mallinckrodt Enterprises LLC | $159.69 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $133.63 | 2022 | |
| Amgen INC. | $118.88 | 2024-2025 | Tepezza |
| Eyevance Pharmaceuticals LLC | $108.07 | 2022-2023 | Flarex |
| Samsara Vision | $98.84 | 2019 | |
| Carl Zeiss Meditec USA, INC. | $88.92 | 2021 | |
| Harrow Eye, LLC | $70.73 | 2024-2025 | Vevye |
| Biohaven Pharmaceuticals, INC. | $38.56 | 2021 | |
| Pfizer INC. | $37.47 | 2023 | |
| Akorn Operating Company LLC | $33.00 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $23.16 | 2025 | Xdemvy |
| Astellas Pharma Global Development | $22.42 | 2024 | Izervay |
| Carl Zeiss Meditec, INC. | $21.65 | 2021 | |
| Ocular Therapeutix, INC. | $19.60 | 2021 | |
| Akorn, INC. | $17.78 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randal Pham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.